Loading...
Anand Agricultural University, Anand
Anand Agricultural University (AAU) was established in 2004 at Anand with the support of the Government of Gujarat, Act No.(Guj 5 of 2004) dated April 29, 2004. Caved out of the erstwhile Gujarat Agricultural University (GAU), the dream institution of Sardar Vallabhbhai Patel and Dr. K. M. Munshi, the AAU was set up to provide support to the farming community in three facets namely education, research and extension activities in Agriculture, Horticulture Engineering, product Processing and Home Science. At present there seven Colleges, seventeen Research Centers and six Extension Education Institute working in nine districts of Gujarat namely Ahmedabad, Anand, Dahod, Kheda, Panchmahal, Vadodara, Mahisagar, Botad and Chhotaudepur
AAU's activities have expanded to span newer commodity sectors such as soil health card, bio-diesel, medicinal plants apart from the mandatory ones like rice, maize, tobacco, vegetable crops, fruit crops, forage crops, animal breeding, nutrition and dairy products etc. the core of AAU's operating philosophy however, continues to create the partnership between the rural people and committed academic as the basic for sustainable rural development. In pursuing its various programmes AAU's overall mission is to promote sustainable growth and economic independence in rural society. AAU aims to do this through education, research and extension education. Thus, AAU works towards the empowerment of the farmers.
Browse
8 results
Search Results
ThesisItem Open Access STUDIES ON EFFECT OF KETOPROFEN AND FEBRILE CONDITION ON PHARMACOKINETICS OF LEVOFLOXACIN AND SAFETY OF LEVOFLOXACIN ALONE AND IN COMBINATION WITH KETOPROFEN IN SHEEP(AAU, Anand, 2009) PATEL, URVESHKUMAR DAHYABHAI; Thaker, A. M.Levofloxacin is a novel third generation fluoroquinolone with broad spectrum antibacterial activity. Use of non-steroidal anti-inflammatory drugs (NSAIDs) are frequently recommended with antibacterials for the treatment of various bacterial infections accompanied by fever and other inflammatory conditions in animals. Ketoprofen (KTP) is an aryl propionic acid derivative, non-selective COX inhibitor NSAID having anti-inflammatory, analgesic and antipyretic properties. In veterinary practice, ketoprofen is used to lower body temperature in animals having fever, to relieve bacteremia and pain in all animals. Pharmacokinetics of an antibacterial drug may change when administered with anti-inflammatory drug or in febrile animals. Despite the great potential for clinical use of levofloxacin, the data on its pharmacokinetics and safety profile in sheep are scarce. The present study was planned to determine the effect of intramuscularly administered ketoprofen (3 mg/kg) and febrile condition (lipopolysaccharide (LPS) induced) on pharmacokinetics of levofloxacin following intravenous, subcutaneous and oral administration (3 mg/kg) in sheep and safety of daily intravenous administration of levofloxacin alone (3 mg/kg) and in combination with intramuscular administration of ketoprofen (3 mg/kg) for five days in sheep by monitoring haematological and blood biochemical profiles.ThesisItem Open Access PHARMACOKINETIC INTERACTIONS OF TOLFENAMIC ACID AND MOXIFLOXACIN AND SAFETY OF TOLFENAMIC ACID IN WISTAR RATS(AAU, Anand, 2009) PATEL, SATISHKUMAR DAHYALAL; Thaker, A. M.Drug interactions may occur when two drugs are concurrently administered and one drug (or both) may influence the time course of the other in the body. Nonsteroidal anti-inflammatory drugs (NSAIDs) and antibacterial agents are prominent among the groups of drugs commonly prescribed together in veterinary medicine and they have enormous potential for drug interactions. Tolfenamic acid is a non-steroidal anti-inflammatory drug (NSAID) of the fenamate sub-group. Moxifloxacin is a novel fourth generation fluoroquinolone with broad spectrum antibacterial activity. The pharmacokinetic of tolfenamic acid (4.0 mg/kg) and moxifloxacin (5 mg/kg) as single drug and in combination after its intramuscular administration was investigated in male and female wistar rats. Tolfenamic acid and moxifloxacin were assayed in plasma by LC-MS/MS. Pharmacokinetic parameters were calculated by noncompartmental technique using computer software (WinNonlin, version 5.0.1). The present study also evaluated safety of tolfenamic acid (4 mg/kg) alone and in combination with moxifloxacin (5.0 mg/kg) after repeated administration at 24 h interval for 14 days in male and female wistar rats. The mean observed peak plasma concentration of tolfenamic acid following its administration as single drug and in combination with moxifloxacin in male rats were 4111.44 ± 493.15 and 3837.69 ± 351.83 ng/ml, where as in female rats mean values were 7114.74± 1409.96 and 7436.37±518.67 ng/ml, respectively, which was observed at 1 h respectively. The mean peak plasma concentration of moxifloxacin following its intramuscular administration as single drug and in combination with tolfenamic acid were 243.52 ± 13.66 and 397.62 ± 41.55 ng/ml, observed at 2 and 0.67 h, respectively in male rats, where as m female rats mean values were 200.74 ±28.67 and 255.88 ± 30.89 ng/ml, observed at 2 and 1 h, respectively. Following intramuscular administration of tolfenamic acid (4 mg/kg) as single drug and in combination with moxifloxacin (5 mg/kg) in male wistar rats the mean values of half-life (t 1/2), volume of distribution (Vz), clearance (CI) and area under plasma drug concentration-time curve (AUC (0-∞)) of tolfenamic acid were 2.59 ±0.16 and 3.27 ± 0.32 hr, 822.17 ± 115.38 and 1249.64 ± 139.52 ml, 218.39 ± 25.47 and 265.18 ± 11.36 ml/hr and 20280.77 ± 3501.67 and 15229.18 ± 678.80 hr.ng/ml, respectively. Whereas in female rats mean values of tolfenamic acid were 2.78 ± 0.39 and 2.66 ± 0.53 hr, 756.42 ± 166.09 and 559.68 ±76.19 ml, 179.76 ± 20.01 and 152.75 ± 10.34 ml/hr and 23524.07 ± 2324.79 and 26830.41 ± 1914.84 hr.ng/ml, respectively. Volume of distribution (Vz) was significantly higher in male rats following concurrent intramuscular administration of tolfenamic acid and moxifloxacin. Following intramuscular administration of moxifloxacin alone in male rats, the mean volume of distribution, half-life (t1/2), area under the plasma drug concentration time curve from 0.0 hr to infinity (AUC (0-∞)) and total clearance (CI) were 12679.07 ± 1121.74 ml, 2.52 ± 0.23 h, 1483.21 ± 184.65 hr.ng/ml and 3605.99 ± 394.29 ml/hr, respectively. Following intramuscular administration of moxifloxacin in combination with tolfenamic acid in male rats significant decrease in elimination half-life (ti/2: 1.69 ± 0.21 h) and volume of distribution (Vz: 7856.51 ± 495.60 ml) has been observed compared to moxitloxacin treatment alone. Following intramuscular administration of moxifloxacin (5 mg/kg) as single drug and in combination with tolfenamic acid (4 mg/kg) in female wistar rats the mean values of half-life (t1/2), volume of distribution (Vz), clearance (CI) and area under plasma drug concentration-time curve (AUC (0-∞)) of moxifloxacin were 1.98 ± 0.38 and 1.44 ± 0.21 hr, 15005.77 ± 2939.77 and 12488.86 ± 1708.16 ml, 5360.93 ± 502.91 and 6163.69 ± 563.64 ml/hr and 975.84 ± 93.57 and 851.60 ± 90.61 hr.ng/ml. respectively. There were non significant difference (p<0.05) in pharmacokinetic parameters of moxifloxacin in female rats following concurrent intramuscular administration with tolfenamic acid as compared to moxifloxacin. Repeated intramuscular administration of tolfenamic acid (4 mg/kg) alone and in combination with moxifloxacin (5 mg/kg) repeated at 24 h interval for 14 days in male and female wistar rats were found safe based on evaluation of haematological (Hb, RBC, WBC, MCV, MCH, MCHC, HCT and DLC), blood biochemical (AST, ALT, ALP, total bilirubin, total serum protein, serum albumin, globulin, serum creatinine, urea, uric acid and blood glucose) parameters. Moreover, no gross or microscopic changes were found in the liver, kidney, heart, spleen, stomach, intestine and joint cartilages of male and female wistar rats. The present study revealed that administration of tolfenamic acid and moxifloxacin together altered pharmacokinetic profile of each other. Therefore, concomitant use of both the drugs requires therapeutic monitoring for potential pharmacokinetic drug interaction.ThesisItem Open Access STUDIES ON PHARMACOKINETICS, BIOAVAILABILITY AND SAFETY OF KETOPROFEN IN SHEEP(AAU, Anand, 2008) GONDALIYA, SANJAY RAMESHBHAI; BHAVSAR, S. K.Levofloxacin is the active L - isomer of the racemate ofloxacin, a fluorinated quinolone has broad-spectrum activity and good antiKetoprofen is a non steroidal anti-inflammatory drug (NSAID) used for its antiinflammatory, analgesic and antipyretic properties in Veterinary medicine. The pharmacokinetics of ketoprofen after its single dose intravenous and intramuscular administration was investigated in six patanwadi breed of sheep by non compartmental approach. The drug was administered at the dose rate of 3.0 mg.kg-1 body weight and assayed in plasma by HPLC analysis. The present study also evaluated safety of ketoprofen (3.0 mg.kg-1) after repeated administration at 24 h interval for 5 days in sheep. Following intravenous and intramuscular administration of ketoprofen, values of elimination half-life (t1/2β), volume of distribution of drug at steady state [Vd(ss)], total body clearance (CIB), area under plasma drug concentration-time curve (AUC), and mean residence time (MRT) were 1.66 ± 0.12 and 3.31 ± 0.16 h; 0.31 ± 0.01 and 0.83 ± 0.08 L.kg-1; 5.53 ± 0.27 and 3.85 ± 0.30 ml.min-1.kg-1; 9.32 ± 0.32 and 13.58 ± 0.91 ng.h.ml-1 and 1.00 ± 0.06 and 3.67 ± 0.41 h, respectively. Following intramuscular administrationacterial activity at low plasma/tissue concentration. The present study was designed to investigate pharmacokinetics of levofloxacin following single dose intravenous and oral administration at the dose rate of 10 mg/kg of body weight and to evaluate safety after repeated administration (10 mg/kg) of levofloxacin at 12 hours interval for 14 days in layer birds. Drug concentration in serum was determined using High Performance Liquid Chromatography (HPLC). Following intravenous administration, the serum drug concentration-time curves were analyzed by non-compartmental approach. Following intravenous administration the therapeutically effective serum concentration of levofloxacm > 0.13 µg/ml was maintamed for up to 12 hours. Based on the serum drug concentrations, various pharmacokinetic parameters like elimination half-life (t1/2β) (3.08 ± 0.05 hours), apparent volume of distribution (Vd(area)) (4.02 ± 0.079 1/kg), volume of distribution of drug at steady-state (Vd(ss)) (3.23 ± 0.055 1/kg), total body clearance (CIB) (15.09 ± 0.21 ml/min/kg), area under serum drug concentration-time curve (AUG) (11.07 ± 0.14 µg.h/ml), area under first moment of curve (AUMC) (39.56 ± 0.89 µg.h2/ml) and mean residence time (MRT) (3.57 ± 0.052 hours) were determined. peak plasma concentration (Cmax) of 4.91 ± 0.52 was achieved at 0.5 h (tmax)- Bioavailability of the drug was 73.16 ± 5.58. Longer elimination half-life, larger volume of distribution at steady state and slower total body clearance of ketoprofen following intramuscular administration as compared to intravenous administration makes it more suitable for intramuscular use in sheep. Repeated intravenous administration of ketoprofen (3.0 mg.kg-1 body weight repeated at 24 h interval for 5 days) in sheep was found safe based on evaluation of haematological (Hb, PCV, TLC and DLC) and blood biochemical (AKP, ACP, AST, ALT, LDH, Total Bilirubin, Serum Creatinine, Total Serum Protein, Serum Albumin and Blood glucose) parameters except BUN. It is advisable to monitor kidney functions during long term therapy with ketoprofen in sheep. The present study indicate that intramuscular administration of ketoprofen at dose rate of 3.0 mg.kg'-1 in sheep would be provide a satisfactory plasma concentration of drug equal to its median effective concentration up to 18 h. Therefore, ketoprofen given via intramuscular route at the dose rate of 3.0 mg.kg-1 of body weight repeated every 18 h would be satisfactory therapeutic dosage regimen for sheep. However, therapeutic efficacy of the dosage remains to be evaluated in clinical cases under field conditions.ThesisItem Open Access STUDY OF EFFICACY AND TOXICITY OF ROSUVASTATIN IN NORMAL AND HIGH FAT-HIGH CHOLESTEROL DIET FED HAMSTERS(AAU, Anand, 2009) GOTHI, ANIL KALIDAS; Thaker, A. M.Rosuvastatin, a new statin is indicated for the treatment of dyslipidemia. The present study was conducted to evaluate the efficacy and toxicity of rosuvastatin in normal and high fat-high cholesterol diet fed (dyslipidemic) hamsters. The study was conducted on 86 male Golden Syrian hamsters. The animals were administered with rosuvastatin at 1, 10, 25, 50 and 100 mg/kg doses in normal diet fed hamsters and at 0.1, 0.3, 0.5, 1 and 1.5 mg/kg doses in high fat high cholesterol diet fed hamsters. The animals were observed throughout the experimental period for any toxic manifestation and daily body weight was recorded to see the effect. At 0, 7th and 14th days of treatment, animals were subjected to blood collection and serum sample were analyzed for different biochemical parameters. At the end of treatment period animals were sacrificed and necropsy was performed, and tissues were collected (heart, liver, kidney and muscle) for histopathological studies. Dyslipidemic animal model was developed after feeding of high fat high cholesterol diet for 14 days. In this dyslipidemic animal model serum concentration of triglyceride, total cholesterol and low density lipoprotein cholesterol level increased by 2.5, 3, and 4 fold as compared to normal diet fed hamsters. Body weight was significantly decreased at 100 mg/kg dose in normal hamsters and, at 1 and 1.5 mg/kg dose in dyslipidemic hamsters. Rosuvastatin produced significant hypotriglyceridemia at 50 and 100 mg/kg dose in normal hamsters and, at 0.3, 0.5, 1.0 and 1.5 mg/kg dose in dyslipidemic hamsters. Rosuvastatin at 100 mg/kg dose produced significant hypocholesterolemia in normal hamsters while, at 0.1, 0.3, 0.5, 1.0 and 1.5 mg/kg dose there was no reduction in total cholesterol. Rosuvastatin produced good efficacy means significant reduction in low density lipoprotein cholesterol at 50 and 100 mg/kg doses in normal hamsters, while at 1.0 and 1.5 mg/kg doses in dyslipidemic hamsters. High density lipoprotein cholesterol level significantly decreased in normal hamsters at 100 mg/kg dose, while in dyslipidemic hamsters it was significantly increased at 1.0 and 1.5 mg/kg doses. Low density lipoprotein to high density lipoprotein cholesterol ratio was significantly reduced at 100 mg/kg dose in normal hamsters, and at 1 and 1.5 mg/kg dose in dyslipidemic hamsters. Aspartate aminotransferase and alanine aminotransferase level were significantly increased at 50 and 100 mg/kg dose in normal hamsters while, at 0.5,1.0 and 1.5 mg/kg dose in dyslipidemic hamsters. Alkaline phosphatase and total bilirubin levels were significantly increased at 100 mg/kg dose in normal hamsters while at 1 and 1.5 mg/kg dose in dyslipidemic hamsters. It was clearly indicated that liver toxicity of rosuvastatin was higher in dyslipidemic animal model. There was no significant treatment related changes in Serum creatine kinase level in both normal and dyslipidemic hamsters. Liver weight was significantly increased at doses of 50 and 100 mg/kg in normal hamsters whereas; it was decreased at 0.3, 0.5, 1 and 1.5 mg/kg doses in dyslipidemic hamsters. Kidney weight was significantly increased at 100 mg/kg dose in normal hamsters and, at 0.3, 0.5, 1 and 1.5 mg/kg doses in dyslipidemic hamsters. Gross postmortem changes, observed in high dose group (50 and 100 mg/kg) of rosuvastatin were mottled liver in normal hamsters. In high fat high cholesterol diet fed hamsters all treatment groups along with control group, all animals showed pale and mottled liver. In dyslipidemic hamsters rosuvastatin at 1.0 and 1.5 mg/kg dose showed dark red colour kidney and marked muscle wasting condition. Microscopic changes observed in liver were necrosis of hepatocyte, mononuclear cells infiltration and cytoplasmic vacuolization at 25, 50 and 100 mg/kg doses in normal hamsters, while inflammatory cell infiltration, fatty changes, bile duct proliferation and hepatic necrosis was observed at 0.5, 1 and 1.5 mg/kg doses in dyslipidemic hamsters. Skeletal muscles showed segmental muscle fiber degeneration in 50 and 100 mg/kg dose groups of normal hamsters and 1 and 1.5 mg/kg dose groups of dyslipidemic hamsters. Heart showed myocardial degeneration and necrosis at 25, 50 and 100 mg/kg dose in normal hamsters and, at 0.5, 1 and 1.5 mg/kg dose in dyslipidemic hamsters. Kidney showed renal tubular degeneration in normal hamsters at 25, 50 and 100 mg/kg dose and, at 1 and 1.5 mg/kg dose in dyslipidemic hamsters. In the present study in dyslipidemic hamsters, rosuvastatin, at administered doses, has been found more toxic as compared to normal hamsters.ThesisItem Open Access STUDIES ON PHARMACOKINETIC INTERACTION OF MOXIFLOXACIN AND MELOXICAM AND SAFETY OF MOXIFLOXACIN IN WISTAR RATS(AAU, Anand, 2009) SADARIYA, KAMLESH AMARSHIBHAI; BHAVSAR, S. K.Antibacterial are frequently recommended as an adjunct therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) to treat various bacterial infections accompanied by fever and other inflammatory conditions in animals. Moxifloxacin is a novel fourth generation fluoroquinolone with broad spectrum of antibacterial activity. Meloxicam is a member of the oxicam family of NSAIDs having antiinflammatory, analgesic and antipyretic properties. The pharmacokinetic of Moxifloxacin (5.0 mg/kg) and Meloxicam (0.5 mg/kg) as single drug and in combination after its intramuscular administration was investigated in 36 male and female wistar rats. Moxifloxacin and Meloxicam were assayed in plasma by HPLC. Pharmacokinetic parameters were calculated by non-compartmental technique using computer software (WinNonlin, version 5.0.1). The present study also evaluated safety of Moxifloxacin (5.0 mg/kg) after repeated administration at 24 h interval for 14 days in 24 male and female Wistar rats. The mean peak plasma concentration (Cmax) of Moxifloxacin following its administration as single drug and in combination with Meloxicam in male rats were 301.41 ± 25.07 and 375.72 ± 44.97 ng/ml respectively, which was observed at 1 h. while in female rats mean Cmax of moxifloxacin were 251.43 ± 46.36 and 152.95 ± 4.45 ng/ml respectively, which was observed at 0.67 and 1 h respectively. The mean peak plasma concentration (Cmax) of Meloxicam following its administration as single drug and in combination with Moxifloxacin were 2539.67 ± 160.01 and 1859.01 ± 219.92 ng/ml respectively, in male rats. The mean Cmax values of Meloxicam in female rats were 2018.73 ± 128.52 and 2339.33 ± 149.00 ng/ml respectively, which was observed at 2 h. Peak plasma concentration (Cmax) Meloxicam was significantly lower in male rats following concurrent intramuscular administration of Moxifloxacin and Meloxicam. Following intramuscular administration of Moxifloxacin(5.0 mg/kg) as single drug and in combination with Meloxicam (0.5 mg/kg) in male wistar rats the mean values of half-life (t 1/2), volume of distribution (Vz), clearance (CI) and area under plasma drug concentration-time curve (AUC (o-α)) of Moxifloxacin were 2.27 ± 0.14 and 1.98 ± 0.31 hr, 11051.18 ± 530.11 and 9728.50 ± 1533.39 ml, 3442.16 ± 255.67 and 3632.24 ± 700.00 ml/hr and 1496.67 ± 120.04 and 1575.18 ± 222.45 hr.ng/ml, respectively. Whereas in female rats mean values of Moxifloxacin were 1.95 ± 0.22 and 3.56 ± 0.95 hr, 19526.48 ± 3171.76 and 36868.52 ± 6032.37 ml, 6005.43 ± 1134.19 and 5974.10 ± 1108.59 ml/hr and 1076.79 ± 282.55 and 1028.86 ± 218.83 hr.ng/ml, respectively. Volume of distribution (Vz) was significantly higher in female rats following concurrent intramuscular administration of Moxifloxacin and Meloxicam.ThesisItem Open Access EVALUATION OF GENOTOXICITY FOLLOWING REPEATED ORAL ADMINISTRATION OF CYPERMETHRIN IN WISTAR RATS(AAU, Anand, 2008) MORE, AMAR SUNIL; Thaker, A. M.Pyrethroids have become the most frequently used pesticides because of more stability in light and good insecticidal activity. Cypermethrin is an insecticide of the synthetic pyrethroid family. Over ninety percent of the cypermethrin, manufactured worldwide, is used to kill insects mainly on cotton and other agricultural crops. It is also used on lettuce and pecans to kill cockroaches (and other indoor pests), in buildings and to kill termites. As this insecticide is in use as a crop protectant, it is likely to cause indirect exposure of animals and humans through contaminated feed, soil and water, leading to some biological alterations. Hence present study was conducted to find out genotoxic potential of cypermethrin. The present study was conducted in 60 healthy male and female Wistar rats, which were acclimatized for one week before the start of oral dosing of cypermethrin. Approximate median lethal dose (ALD50) of cypermethrin used for the study was 250 mg/kg body weight. Sixty rats were divided into five different group, each comprising 12 rats. Each group had 6 male and 6 female rats .The groups were numbered as group I to V. The group I was given lower toxic dose of cypermethrin (1/40th part of LD 50 i.e. 6.25 mg/kg) orally by gavaging for 28 days, group II was given medium toxic dose of cypermethrin (1/30th part of LD 50 i.e. 8.33 mg/kg) orally by gavaging for 28 days, group III was given higher toxic dose of cypermethrin (1/20th part of LD 50 i.e. 12.33 mg/kg) orally by gavaging for 28 days, group IV was gavaged with com oil for 28 days and was kept as negative control and group V served as a positive control group and was given cyclophosphamide for genotoxicity study (20 mg/kg) intra peritoneally 24 hours prior to sacrifice. Once daily oral dosing of test compound was carried out for 28 days. All the rats were monitored for any observable toxic symptoms throughout the experimental period and they were also weighed weekly to monitor weight gain. Before sacrificing, the blood samples of rats were collected and were analyzed for percentage comet cells through comet assay test. After sacrification, bone marrow of femur was collected for both micronuclei and chromosomal aberration tests. Micronuclei test was performed on first half i.e. 30 rats and chromosomal aberration test was performed on rest half i.e. another 30 rats. There were noticeable signs and symptoms like pawing, burrowing and tremors. Severity of symptoms was high in animals given high dose of cypermethrin. During the last quarter of the experiment, animals in higher dose groups appeared dull, depressed and anorexic. Besides there was no mortality at all the dose levels of cypermethrin administration. There was no significant effect on body weight gain of the cypermethrin treated rats as compared to control. There was increase in polychromatic erythrocytes with micronuclei when dose of cypermethrin was increased and was significantly higher than vehicle controls at all dose levels. It was also observed that induction of MN in the rats treated with highest dose of cypermethrin was significantly low as compared to cyclophosphamide treated positive group.ThesisItem Open Access STUDIES ON PHARMACOKINETICS, BIOAVAILABILITY AND SAFETY OF KETOPROFEN IN COW CALVES(Anand Agricultural University, 2008) RATN DEEP SINGH; Dr. S.K. BhavsarKetoprofen is a non steroidal anti-inflammatory drug (NSAID) used for its anti-inflammatory, analgesic and antipyretic properties in Veterinary medicine. The pharmacokinetics of ketoprofen after its single dose intravenous and intramuscular administration was investigated in six crossbred cow calves by non compartmental approach. The drug was administered at the dose rate of 3.0 mg.kg-1 body weight and assayed in plasma by HPLC analysis. The present study also evaluated safety of ketoprofen (3.0 mg.kg-1) after repeated administration at 24 h interval for 5 days in calvesThesisItem Open Access “STUDIES ON PHARMACOKINETICS, BIOAVAILABILITY AND SAFETY OF KETOPROFEN IN SHEEP(Anand Agricultural University, 2008) GONDALIYA SANJAY RAMESHBHAI; Dr. S.K. BhavsarKetoprofen is a non steroidal anti-inflammatory drug (NSAID) used for its antiinflammatory, analgesic and antipyretic properties in Veterinary medicine. The pharmacokinetics of ketoprofen after its single dose intravenous and intramuscular administration was investigated in six patanwadi breed of sheep by non compartmental approach. The drug was administered at the dose rate of 3.0 mg.kg-1 body weight and assayed in plasma by HPLC analysis. The present study also evaluated safety of ketoprofen (3.0 mg.kg-1) after repeated administration at 24 h interval for 5 days in sheep